A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Abstract

A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.

DOI: 10.1007/s10165-011-0497-5
0100200300201220132014201520162017
Citations per Year

552 Citations

Semantic Scholar estimates that this publication has 552 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hirano2012ACO, title={A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.}, author={Toru Hirano and Nobuyuki Ohguro and Satoshi Hohki and Keisuke Hagihara and Yoshihito Shima and Masashi Narazaki and Atsushi Ogata and Kazuyuki Yoshizaki and Atsushi Kumanogoh and Tadamitsu Kishimoto and Toshio Tanaka}, journal={Modern rheumatology}, year={2012}, volume={22 2}, pages={298-302} }